Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trialHarold Atkins, Mark S. Freedman, Amit Bar‐Or et al.|The Lancet|2016Cited by 327
Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantationPeter J. Darlington, Tarik Touil, Jean-Sébastien Doucet et al.|Annals of Neurology|2012Cited by 152
Impact of immunoablation and autologous hematopoietic stem cell transplantation on gray and white matter atrophy in multiple sclerosisHyunwoo Lee, Douglas L. Arnold, Sridar Narayanan et al.|Multiple Sclerosis Journal|2017Cited by 21